Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older

Sanofi Pasteur Inc.0 个研究点目标入组 121,000 人开始时间: 2019年7月24日最近更新: 2022年4月19日

适应症

试验速览

暂无简介。

•- Aged 65 years or older on the day of inclusion (65 years means from the day of the 65th birthday)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 121000

•- Participation at the time of study enrollment (or in the 4 weeks [28 days] preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
•- Previous vaccination against influenza (in the preceding 6 months) with either the study vaccines or another vaccine
•- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances

发起方